Fierce 15 member Astute Medical pointed to a study in The Journal of the American Medical Association that used its NephroCheck diagnostic of acute kidney injury to demonstrate that the life-threatening condition can be kept in check by what's known as remote ischemic preconditioning.
Researchers have developed silicon chips that can be implanted in the brain and relay a person's intentions into the movement of robotic prosthetics.
Outside of surgery, physicians can do very little to treat severe rotator cuff tears. Israeli company OrthoSpace is aiming to offer a new treatment option. It's raised an $8 million venture round led by Healthpoint Capital that will finance a pivotal, U.S. trial for the company's biodegradable balloon system InSpace.
Royal Philips and the Academic Medical Center in Amsterdam, the Netherlands, will collaborate in a European multicenter trial of a new diagnostic technique to assess the results of minimally invasive treatment for diabetic foot and critical limb ischemia. The trial is slated to start this summer with final results expected in 2017.
The MD Anderson Cancer Center at Cooper has partnered with behavioral health technology player Polaris Health Directions to start a pilot test using the Apple Watch that integrates patient behavioral data into electronic health records and population health data.
Startup Shockwave Medical expects that its Lithoplasty balloon catheters will emerge as a pretreatment for calcified coronary lesions that's used instead of or prior to stenting. Now it's received $40 million to further advance toward that goal.
Mitral valve replacement is intended to be the next big thing at Edwards Lifesciences, though it's still in the early research stage. But, for now, the company has paused a clinical trial due to safety concerns. Specifically, the company said it has "observed evidence of valve thrombosis" in a clinical trial of its Fortis transcatheter mitral valve replacement device.
Apollo Endosurgery's intragastric balloon doubled weight loss compared to diet and exercise alone during its pivotal clinical trial, the company said during the Digestive Disease Week conference in Washington, DC.
Tracking patients who have various cardiac devices via a remote monitoring system cuts down on hospitalizations and costs, while improving patient survival. That's according to a 5-year study by St. Jude Medical of more than 90,000 patients with pacemakers, implantable cardioverter defibrillators, and cardiac resynchronization therapy devices.
Medtronic touted data on its investigational, MRI-safe implantable defibrillator and leadless pacemaker presented at the Heart Rhythm Society's annual meeting in Boston.